^
Association details:
| Biomarker: | SMARCA4 deletion |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | PRT1419 (MCL1 inhibitor) + PRT3789 (SMARCA2 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
420 / 5 - Combination of the MCL1 inhibitor PRT1419 and SMARCA2 degrader PRT3789 shows combinatorial benefit in SMARCA4 deleted lung cancer420 / 5 - Combination of the MCL1 inhibitor PRT1419 and SMARCA2 degrader PRT3789 shows combinatorial benefit in SMARCA4 deleted lung cancer
Published date:
03/09/2022
Excerpt:
...we evaluated PRT1419 in combination with a novel and selective SMARCA2 degrader, PRT3789, in SMARCA4 deleted lung cancer models…combining PRT1419 and PRT3789 in vivo in cell line-derived xenograft models resulted in significant tumor growth inhibition, including tumor regressions.
